Tralokinumab (Adtralza)

Key Messages

• CADTH recommends that Adtralza should not be reimbursed by public drug plans for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
• Evidence from 4 clinical trials demonstrated that, in the short term, Adtralza treatment improved severity of AD, itch symptoms, and health-related quality of life (HRQoL) compared to placebo in adults and adolescents with moderate to severe AD; however, it is uncertain if the magnitude of benefit is clinically meaningful to patients and clinicians. Additionally, a clinical trial in adults with severe AD whose disease did not adequately respond to, or were deemed unsafe to receive, a systemic immunosuppressant showed that Adtralza treatment improved severity of AD but not itch, and its effects on other clinical outcomes are unclear.
• No evidence that directly compared Adtralza to currently available treatments for AD was submitted. The indirect evidence submitted was uncertain due to limitations of the analyses; therefore, it is unclear whether Adtralza offers a clinically meaningful benefit for patients compared to other treatments for AD.
• The evidence for the effectiveness of Adtralza use in the longer term and in patients who previously received dupilumab and/or Janus kinase inhibitors (JAKis) (i.e., currently existing treatments) was uncertain due to limitations of the study designs and analysis; therefore, the benefits of Adtralza in these scenarios cannot be determined.